文献速递淋巴瘤造血干细胞移植与细胞治疗

自体移植后复发弥漫大B细胞淋巴瘤的复发后生存

Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
PubMed 文献 · Blood Adv · 2019-01-01

该研究利用4个移植中心的数据,纳入2006-2015年自体造血干细胞移植(auto-HCT)后复发的成人弥漫大B细胞淋巴瘤(DLBCL)患者,主要终点为复发后总生存(PR-OS)。700例接受auto-HCT的患者中248例(35%)复发,可评估的228例中位PR-OS为9.8个月(95%CI 7-15)。auto-HCT时达完全缓解、诊断至auto-HCT>1年及晚期复发者PR-OS显著更优,多因素分析中晚期复发与死亡风险降低相关,年龄增长与死亡风险增加相关。

要点

  • auto-HCT后复发DLBCL患者中位PR-OS为9.8个月(95%CI 7-15)。

核心结论

  • auto-HCT后复发的DLBCL患者PR-OS仍较差,中位PR-OS为9.8个月(95%CI 7-15)。
  • auto-HCT时完全缓解、诊断至auto-HCT>1年及晚期复发与更好的PR-OS相关。

研究设计与样本

  • 多中心研究,使用4个移植中心的数据。
  • 纳入2006至2015年期间接受auto-HCT后复发的成人(≥18岁)DLBCL患者。
  • 时间分层为era 1(2006-2010)和era 2(2011-2015)。
  • 700例接受auto-HCT的DLBCL患者中248例(35%)复发,其中228例纳入PR-OS分析。
  • 主要终点为PR-OS,次要终点为PR-OS的预后因素。

主要发现

  • 全部复发DLBCL患者(n=228)中位PR-OS为9.8个月(95%CI 7-15)。

临床怎么用

  • 该研究为迄今评估auto-HCT后复发DLBCL患者结局的最大样本研究。
  • 研究结果为未来嵌合抗原受体T细胞及其他有前景药物的PR-OS试验提供了基准。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Outcomes for diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous hematopoietic cell transplantation (auto-HCT) have been historically poor. We studied outcomes of such patients using data from 4 transplantation centers. Eligibility criteria included adult patients (age ≥18 years) with DLBCL experiencing disease relapse after auto-HCT performed during 2006 to 2015. The time period was stratified into 2 eras (era 1, 2006-2010; era 2, 2011-2015). The primary end point was postrelapse overall survival (PR-OS). Secondary end points were factors prognostic of PR-OS. Of the 700 patients with DLBCL who underwent auto-HCT, 248 (35%) relapsed after auto-HCT. Median PR-OS of all relapsed DLBCL patients after auto-HCT (n = 228) was 9.8 months (95% confidence interval [CI], 7-15). Median PR-OS was significantly better for patients in complete (17.8 months; 95% CI, 7.9-41.6) vs partial remission at auto-HCT (7.1 months; 95% CI, 5.4-11; P = .01), those undergoing auto-HCT >1 year (12.8 months; 95% CI, 7.6-24.9) vs ≤1 year after DLBCL diagnosis (6.3 months; 95% CI, 4.5-9.2; P = .01), and those with late (56.4 months; 95% CI, 23.7-∞) vs early relapse (5.9 months; 95% CI, 4.5-8.8; P < .0001). On multivariate analysis, although late relapse (hazard ratio [HR], 0.21; 95% CI, 0.13-0.34; P < .0001) was associated with significantly lower mortality, the risk of mortality increased with age (HR, 1.25 per decade; 95% CI, 1.06-1.48; P = .009). This is the largest study to date to evaluate outcomes of DLBCL patients relapsing after auto-HCT. Our study provides benchmarking for future trials of chimeric antigen receptor T cells and other promising agents evaluating PR-OS after auto-HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Epperla N, Badar T, Szabo A, et al. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019. PMID: 31167818. doi:10.1182/bloodadvances.2019000102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。